Bispecific antibodies (bsAbs) utilize the properties of two antibodies and integrate them for parallel recognition of various antigens or epitopes. Such a “two-target” functionality implies that the interest in their use for therapeutic applications has grown remarkably.

The development and maturity of the bsAb technology stage have made the combination selection of targets a primary aspect of competition. Currently, among the bsAb programs under development, the combination of CD3 and tumor surface targets is the most popular target pair. The new targets of the immune cells are also capable of offering more options in targets combination in the future.

Hot targets

Targets for bispecific antibodies

Image Credit: ACROBiosystems

Free samples are available for bsAb hot targets.

CD3 proteins

Features

  • Delivers high bioactivity and batch-to-batch consistency
  • Bioactivity verified using clinical bispecific antibody
  • MALS verified heterodimer
  • Comprise several tags and species
Targets for bispecific antibodies

Image Credit: ACROBiosystems

Table 1. Source: ACROBiosystems

Molecule Cat. No. Species Product Description Structure
CD3E & CD3D CDD-H5255 HEK293 Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc Tag&Fc Tag (MALS verified)New
CDD-H52Wa HEK293 Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified)Hot
CDD-H82W6 HEK293 Biotinylated Human CD3 epsilon&CD3 delta Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)Hot
CDD-H52W1 HEK293 Human CD3 epsilon & CD3 delta Heterodimer Protein, His Tag&Tag Free (MALS verified)Hot
CDD-H5258 HEK293 Human CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin
CDD-H82F6 HEK293 Biotinylated Human CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His,Avitag™&Fc,Flag,Avitag™ (MALS verified)
CDD-H82W0 HEK293 Biotinylated Human CD3E&CD3D Heterodimer Protein, Fc,His Tag&Fc,Flag Tag, ultra sensitivity (primary amine labeling) (MALS verified)
CDD-C5259 HEK293 Cynomolgus CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin
CDD-C52W4 HEK293 Cynomolgus CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified)
CDD-C52W9 HEK293 Cynomolgus CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified)
CDD-C82W6 HEK293 Biotinylated Cynomolgus CD3E&CD3D Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)
CDD-M5219 HEK293 Mouse CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified)
CDD-M52W2 HEK293 Mouse CD3 epsilon&CD3 delta Heterodimer Protein, Fc,His Tag&Fc,Flag Tag (MALS verified)
CDD-M82W5 HEK293 Biotinylated Mouse CD3 epsilon&CD3 delta Heterodimer Protein, His,Avitag™&Tag Free
CDD-R5257 HEK293 Rat CD3 epsilon&CD3 delta Heterodimer Protein, Llama Fc Tag&Llama Fc Tag (MALS verified)
CDD-R52D8 HEK293 Rat CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified)
CDD-R5259 HEK293 Rabbit CD3E&CD3D Heterodimer Protein, Llama Fc&Llama Fc, low endotoxin (MALS verified)
CDD-R52D7 HEK293 Rabbit CD3 epsilon&CD3 delta Heterodimer Protein, His Tag&Flag Tag (MALS verified)
MBS-K003   Human CD3E & CD3D Heterodimer-coupled Magnetic Beads  

 

PD-1/PD-L1 proteins

Features

  • High bioactivity verified
  • High purity and homogeneity
  • Different tags and species
Targets for bispecific antibodies

Image Credit: ACROBiosystems

CD47 proteins

Features

  • High bioactivity verified
  • High purity and homogeneity
  • Ideal for immunization and inhibitor
Targets for bispecific antibodies

Image Credit: ACROBiosystems

Full-length CD20 proteins

Features

  • Superior bioactivity verified
  • Authentic conformation
  • Unique nanodisk technology
Targets for bispecific antibodies

Image Credit: ACROBiosystems

Bioactivity analysis of bispecific antibody

It is important to perform characterization and pharmacokinetic (PK)/PD assessment. Quality factors such as antigen specificity; affinity and on- and off-rates; avidity (for bispecific antibodies that target two molecules on the same cell); potency; process-related impurities such as aggregates, fragments, and homodimers; stability; and half-life may affect pharmacology and should be analyzed.

However, bispecific antibodies may occur as a blend of biologically active and inactive forms. Hence, it is significant to determine the bispecific antibody form(s) that is pharmacologically relevant to PK/PD test and make confirmed assays that can evaluate the suitable form(s) accordingly.

The synergetic effect caused by BsAb makes the dosage relatively low and hence requires a more sensitive assay for analysis.

Case study 1: Antigen-antibody affinity

Targets for bispecific antibodies

Figure 1. Immobilized Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-H52W1) at 2 μg/mL, add increasing concentrations of Bispecific T cell Engager (CD3 X BCMA) and then add Biotinylated BCMA Fc, Avitag (Cat. No. BC7-H82F0) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 4 ng/mL. Image Credit: ACROBiosystems

Case study 2: FcR-antibody affinity

Targets for bispecific antibodies
Binding assay between bsAb and Fc receptor.

Figure 2. Binding assay between bsAb and Fc receptor. Image Credit: ACROBiosystems

Case study 3: Intact assay of bsAb

Targets for bispecific antibodies

Figure 3. Immobilized Human OX40 Protein, His Tag (MALS verified) (Cat. No. OX0-H5224) at 2 μg/mL, add increasing concentrations of CTLA-4 x OX40 bispecific antibody in 50% Human serum and then add Biotinylated Human CTLA-4, Fc, Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 4 ng/mL (Intact assay). Image Credit: ACROBiosystems

Methodology validation

Table 2. Source: ACROBiosystems

Methodology Validation